No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
GH Guardant Health
- 29.940
- -0.560-1.84%
Close Jun 18 16:00 ET
- 30.310
- +0.370+1.24%
Post 19:35 ET
3.66BMarket Cap-7637P/E (TTM)
31.000High29.790Low1.71MVolume30.210Open30.500Pre Close51.60MTurnover1.56%Turnover RatioLossP/E (Static)122.37MShares41.06052wk High53.66P/B3.29BFloat Cap15.81052wk Low--Dividend TTM109.79MShs Float181.070Historical High--Div YieldTTM3.97%Amplitude15.810Historical Low30.203Avg Price1Lot Size
Full Hours
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Even After Rising 7.4% This Past Week, Guardant Health (NASDAQ:GH) Shareholders Are Still Down 74% Over the Past Three Years
United States Liquid Biopsy Market Forecast to 2031: Company Profiles, Recent Developments and Major Deals - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--The "United States Liquid Biopsy Market (by Circulating Biomarker, Product, Application, Cancer Types, Non-Cancer Application, End User, Clinical Application, Sample Type), In
Guardant Health(GH.US) Director Sells US$2,787 in Common Stock
$Guardant Health(GH.US)$ Director Joyce Meghan V. sold 100 shares of common stock on Jun 4, 2024 at an average price of $27.87 for a total value of $2,787.Source: Announcement What is statement of cha
Express News | Guardant Health Shares Are Trading Higher After the Company Launched the New Guardant360 TissueNext Test. Additionally, Canaccord Genuity Maintained a Buy Rating While Raising Its Price Target to $38
Guardant Health Is Maintained at Buy by Canaccord Genuity
Guardant Health Is Maintained at Buy by Canaccord Genuity
Express News | Canaccord Genuity Maintains Buy on Guardant Health, Raises Price Target to $38
Comments
Guardant Health is undervalued, making it a good time to accumulate more holdings. The company's positive future outlook isn't fully reflected in the current share price. Consider financial health before investing.
Is There Now An Opportunity In Guardant Health, Inc. (NASDAQ:GH)? 1
The recent share price drop may indicate unresolved challenges, despite the company's revenue growth. Investors are advised to ensure they are buying a high-quality business, even when the share price is low.
Guardant Health's high P/S ratio is due to strong revenue performance and promising future growth rates, bolstering shareholder confidence. Given the optimism, a significant stock price drop is unlikely soon.
Substantial insider acquisitions point to optimism for the company's prospects. However, the recent sale by the CIO may suggest some insiders think shares are overvalued. Still, high insider ownership implies alignment of management's interests with shareholders.
Wolfe Research Downgrades $Snowflake(SNOW.US$ to Peer Perform From Outperform
Snowflake (SNOW) has an average rating of outperform and price targets ranging from $105 to $500, according to analysts polled by Capital IQ.
Guggenheim Downgrades $MongoDB(MDB.US$ to Sell From Neutral, Adjusts Price Target to $210 From $205
MongoDB (MDB) has an average rating of outperform and price targets ranging from $180 to $365, according to analysts po...
Snowflake (SNOW) has an average rating of outperform and price targets ranging from $105 to $500, according to analysts polled by Capital IQ.
Guggenheim Downgrades $MongoDB(MDB.US$ to Sell From Neutral, Adjusts Price Target to $210 From $205
MongoDB (MDB) has an average rating of outperform and price targets ranging from $180 to $365, according to analysts po...
18
1
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg